IREN · Investment summary · as of 3 August 2026
Priced slightly ahead of what the business has demonstrated
Business type: Transition · scaling but economically observable
The evidence needed to judge business quality is not established, so the underwriting supports no position.
At $39.76, IREN requires a 50% five-year revenue growth rate to justify its enterprise value — more than the business has ever demonstrated, at 35%.
Revenue path to ~$4bn ARR is substantially signed (Tier 1); the market disagreement is terminal economics (margin, renewal, exit multiple), not revenue arrival.
The value rests on an exit multiple of 6.5x, a terminal operating margin of 27% and a 11.6% cost of capital. Move any one of them materially and the conclusion moves with it, which is why the required-versus-demonstrated test above carries more weight here than the point value.
The strongest argument against this view: Delivery/financing failure on the contracted book: Horizon 1-4 commissioning slips or GPU-collateral squeeze on the $3.6bn secured facility forces a dilutive raise into a falling price with >$11.9bn of commitments outstanding.
| Question | Evidence-based conclusion |
|---|---|
| What drives the business? | Revenue path to ~$4bn ARR is substantially signed (Tier 1); the market disagreement is terminal economics (margin, renewal, exit multiple), not revenue arrival. |
| What do we forecast? | Revenue growth of 35% demonstrated; a terminal operating margin of 27%; an exit multiple of 6.5x. |
| What does Street forecast? | Not determined — no consensus estimates are joined to this record |
| Where do we differ? | On terminal margin, the difference between what the price requires and what the business has demonstrated is -17.1 percentage points. |
| What is it worth? | Twelve-month target $45.00, +13% from the struck price. |
| Why now? | Date not announced — no dated event that would resolve the disagreement is on file |
Date not announced — no dated event that would resolve the disagreement is on file
Delivery/financing failure on the contracted book: Horizon 1-4 commissioning slips or GPU-collateral squeeze on the $3.6bn secured facility forces a dilutive raise into a falling price with >$11.9bn of commitments outstanding.
Estimated probability 20%, against the 17% level at which the position would be resized. It sits above that level, so this case could not be carried at full size.
Falsifiable and fundamental — not one of them is a price condition.
On approach to the $45.00 target the case is reviewed rather than added to; a target reached is a reason to re-examine the position, not to hold it by default.
| Criteria | Status | Investment meaning |
|---|---|---|
| Quality | Not determined | Is the business worth owning under its declared economic type? Not established on the evidence on file. |
| Valuation | Not determined | Is the operating path required by today's price achievable? Not established on the evidence on file. |
| Liquidity | Met | Can the intended position be built and exited in the right vehicle? |
| Downside | Met | Delivery/financing failure on the contracted book: Horizon 1-4 commissioning slips or GPU-collateral squeeze on the $3.6bn secured facility forces a dilutive raise into a falling price with >$11.9bn of commitments outstanding. |
| Momentum | Not determined | Does price action support or complicate entry timing? Not established on the evidence on file. |
| Catalyst | Not determined | Is there a dated event that resolves the disagreement? Not established on the evidence on file. |
| Consensus | Not determined | Is the house-versus-Street disagreement identified and quantified? Not established on the evidence on file. |
Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.
The gap between what today's price requires and what the business has demonstrated is -17.1 percentage points, and that gap — not the multiple — is the case that the security is mispriced. The most important unresolved uncertainty is whether this is a business worth owning at all — the evidence for its quality is not established. The next evidence that should change the portfolio decision is the next scheduled results, or a daily close below $29.82, which forces an immediate review.